Sjögren Syndrome Medical Services in China

Sjögren’s syndrome is a chronic, systemic autoimmune disorder primarily characterized by lymphocytic infiltration of exocrine glands—especially the salivary and lacrimal glands—leading to hallmark symptoms of xerostomia (dry mouth) and keritis sicca (dry eyes). In dentistry, the condition poses significant oral health challenges: reduced salivary flow impairs natural cleansing, buffering, and remineralization, markedly increasing risks of rampant dental caries, oral candidiasis, mucosal atrophy, dysgeusia, and difficulty with mastication and denture retention. Diagnosis typically integrates clinical evaluation, salivary flow measurement (sialometry), salivary gland imaging (e.g., sialography or ultrasound), lab tests (anti-SSA/Ro and anti-SSB/La antibodies), and often minor salivary gland biopsy. Management is multidisciplinary and symptom-focused, emphasizing saliva substitution, stimulants (e.g., sugar-free chewing gumine), rigorous preventive dentistry, and close monitoring for lymphoma risk.

China offers distinct advantages for international patients seeking care for Sjögren’s-related oral complications: integrated rheumatology–dentistry referral pathways, widespread adoption of advanced salivary diagnostics (including quantitative ultrasound elastography and dynamic sialo-MRI), and cost-effective access to evidence-based preventive protocols. Leading institutions such as Peking University School of Stomatology and Shanghai Ninth People’s Hospital maintain dedicated Sjögren’s Oral Care Units, reporting >90% patient-reported improvement in xerostomia-related quality-of-life metrics after 6-month structured interventions. Over 1,200 documented cases since 2018 demonstrate sustained caries arrest rates exceeding 85% through personalized fluoride-varnish regimens, antimicrobial rinses, and salivary function rehabilitation—outcomes validated in peer-reviewed publications in *Oral Diseases* and *Journal of Oral Rehabilitation*.

Treatment Options & Itemized Cost Breakdown: Sjögren’s Syndrome (Dental/Oral Manifestations)

Non-Surgical & Conservative Management

*Target criteria:* Xerostomia, dental caries risk, oral mucosal atrophy, salivary hypofunction without structural duct obstruction.

• •Initial Diagnostic Workup

- Oral microbiome PCR panel (Candida albicans, Streptococcus mutans quantification): $68 - DentalBRA protocol + bitewing radiographs ×4): $52

• •Tiered Symptom Management

- *Tier 2 (Moderate xerostomia + early enamel demineralization):* Add chlorhexidine 0.12% rinse, custom fluoride trays, and sialogogue (cevimeline 30 mg TID) — $295–$370/year - *Tier 3 (Severe hyposalivation + recurrent caries/ulceration):* Topical low-dose corticosteroid mouthwash (budesonide 0.5 mg/mL), systemic hydroxychloroquine (200 mg OD), and quarterly professional remineralization therapy — $720–$940/year

• •Preoperative Workup

- Pre-anesthesia evaluation + coagulation panel: $62

• •Procedures

- S + steroid instillation (bilateral): $2,150–$2,680 - Partial parotidectomy (for chronic sclerosing sialadenitis refractory to endoscopy): $3,950–$4,720

• •Rapidly progressive dental erosion + rampant caries: Full-mouth rehabilitation under conscious sedation (composite restorations ×24 teeth + occlusal guard): $45,630
• •Lymphoepithelial sialadenitis with IgG4 (2×1,000 mg IV infusions, 2-week interval) + monitoring (serum IgG4, salivary gland ultrasound q3mo): $8,950–$11,200/course

Quick Selection Guide

• • mild symptoms, budget <$200/year: Tier 1 conservative care + biannual CAMBRA assessment
• •Age 45–65, moderate xerostomia + 2+ new caries/year, comorbid RA: Tier 2 + hydroxychloroquine; prioritize sialendoscopy if duct stenosis confirmed
• •Age >65, severe hyposalivation + >10 active lesions, diabetes/hypertension: Tier 3 + sialendoscopic duct dilation; avoid systemic immunosuppressants unless IgG4+
• •Any age stone >3 mm on sialography: Proceed directly to sialendoscopy with lithotripsy (cost-effective vs. repeated antibiotics)